State Street Corp Increases Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

State Street Corp grew its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 61.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,004,993 shares of the biotechnology company’s stock after buying an additional 4,945,063 shares during the period. State Street Corp owned 5.58% of ADMA Biologics worth $259,970,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ADMA. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after purchasing an additional 80,400 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the last quarter. Citigroup Inc. grew its position in shares of ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after buying an additional 277,138 shares during the last quarter. Seven Eight Capital LP bought a new stake in shares of ADMA Biologics during the 2nd quarter valued at about $1,992,000. Finally, Principal Financial Group Inc. grew its position in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ADMA. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright upped their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Stock Up 1.1 %

ADMA stock opened at $19.21 on Wednesday. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The firm has a market cap of $4.54 billion, a PE ratio of 68.61 and a beta of 0.70. The firm has a 50 day simple moving average of $19.07 and a 200 day simple moving average of $15.90. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the prior year, the firm earned $0.01 EPS. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.